IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal

2 March 2016

The European Biosimilars Group Appoints New Leadership Team With Sandoz’ Carol Lynch and Polpharma’s Klaus Martin

10 February 2016

Last week in Brussels, the European Biosimilar medicines Group (EBG […]

EGA Welcomes the Delegated Regulation as a Tool To Fight Counterfait Medicines

9 February 2016

Brussels – The European Generic and Biosimilar Medicines Association (EGA) welcomes […]

Shaping The 2020 Regulatory Landscape For Patient Needs

28 January 2016

London – 61 regulators from 25 countries made progress in improving the […]

Industry Coming Together To Improve Safety For Patients

26 January 2016

London – In London this week, the European Generic and Biosimilar medicines […]

Global Pharmaceutical Industry Calls on Governments to Work with Them to Beat the Rising Threat of Drug Resistance

21 January 2016

More than 80 leading international pharmaceutical, generics, diagnostics and biotechnology […]

Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance

21 January 2016

Antimicrobials, and specifically antibiotics, play a crucial role in modern […]

Spain and Europe Join Forces To Bring Access To Generic Medicines To The Market

19 January 2016

Barcelona – At their joint Executive meeting in Barcelona today, the […]

Ethics: EGA Adopts Disclosure Requirements For The Generic, Biosimilar And Value Added Medicines Industry

15 January 2016

Brussels – Today, EGA members unanimously adopted disclosure rules for the […]

Generic and Biosimilar Medicines Essential for Italian Healthcare System

8 January 2016

Brussels – Generic and biosimilar medicines represent an essential opportunity to […]